| Literature DB >> 28871124 |
Chao Zheng1,2,3,4,5, Yuetong Wang1,2,3, Liu Yang1,2,3, Shuhua Zhou2, Yijun Gao1,2,3, Fuming Li1,2,3, Yan Feng1,2,3, Zuoyun Wang1,2,3, Lixing Zhan6, Qin Yan7, Xueliang Zhu1,2,3, Kwok-Kin Wong8,9, Zhengjun Chen10,11,12, Hongbin Ji13,14,15,16.
Abstract
Cell division cycle 42 (CDC42) plays important roles in polarity establishment and maintenance as well as cell cycle progression and cell division. Although disruption of cell polarity is a prerequisite in epithelial tumor initiation, the roles of CDC42 in tumorigenesis are still poorly understood. Here we find that Cdc42 deficiency inhibits the Kras G12D -induced lung alveoli tumor formation, while conversely promotes bronchiole tumor formation in mice. Bronchial Cdc42 loss destroys contact inhibition potentially through cell polarity disruption, and results in increased tumor formation. In contrast, deletion of Cdc42 in alveoli cells prevents Kras G12D -induced cell proliferation, which leads to reduced tumor formation. Further analyses of clinical specimens uncover a significant positive correlation between CDC42 and type II alveolar epithelial cells marker SP-A, indicating the potential importance of CDC42 in this specific subset of lung cancer. Collectively, we identify the lineage-specific function of CDC42 in lung tumorigenesis potentially through the regulation of cell polarity integrity.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28871124 PMCID: PMC5583260 DOI: 10.1038/s41598-017-10891-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Cdc42 loss promotes bronchiole tumor formation but inhibits alveoli tumor formation in Kras mouse model. (a) Mouse number analyzed for 3 strains in indicated time points. (b) Up: PCR analysis of conditional Cdc42 allele recombination in tumors from Kras and Kras/Cdc42 mice; Bottom: Western blot of CDC42 expression in tumors from Kras and Kras/Cdc42 mice. Histone 3 (H3) serves as a loading control. The cropped blots are used in the figure. The membranes were cut prior to exposure so that only the portion of gel containing desired bands would be visualized. (c) Representative histology of lung tumors from WT mice and Cdc42 L/L mice at 80 weeks post Ad-cre treatment. Scale bar = 500 μm. (d) Representative pathology of lung tumors from Kras and Kras/Cdc42 mice at 16 weeks post Ad-Cre treatment. The areas in the boxes of left photos were amplified on the right. Scale bar (left) = 500 μm, Scale bar (right) = 100 μm (e,f) Statistical analyses of the number of alveolar and bronchiolar tumors (e) and the percentage of bronchiolar tumors (f) in Kras and Kras/Cdc42 mice at 16 weeks post Ad-Cre treatment. Al: alveolar; Br: Bronchiolar. Data were shown as mean ± s.e.m. *P < 0.01***P < 0.001. (g) Representative immunostaining of KI-67 in alveolar and bronchiolar tumors from Kras and Kras/Cdc42 mice. Scale bar = 50 μm. (h) Statistical analyses of proliferative index by KI-67 immunostraining in bronchiolar and alveolar tumor lesions from Kras and Kras/Cdc42 mice. More than 200 high-power fields (HPF) per mouse were counted. Data were shown as mean ± s.e.m. ***P < 0.001.
Figure 2Cdc42 loss disrupts bronchiole cell polarity. (a) Immunofluorescent co-staining of ZO1 (Green), Phalloidin (Red) and 4′,6-diamidino-2-phenylindole (DAPI, blue) in Kras and Kras/Cdc42 mice at 3 weeks post Ad-Cre treatment. The arrows indicate tight junctions at apical surface of bronchiole epithelial cells, and the dashed lines indicate basal surface. Scale bar = 3.5 μm. (b) Immunofluorescent staining of Occludin and PAR6 in Kras and Kras/Cdc42 mice at 3 weeks post Ad-cre treatment. The arrows indicate apical surface of bronchiole epithelial cells. Scale bar = 50 μm. (c) Ultrastructural analysis of tight junction between bronchiole cells in WT, Kras, Cdc42 (dashed line) and Kras/Cdc42 (arrows) mice at 3 weeks post Ad-Cre treatment. Scale bar = 500 nm.
Figure 3Cdc42 loss promotes the proliferation of KRAS activated cells potentially through disruption of cell-cell contact inhibition. (a) Immunofluorescent staining of ZO1 (Green) and DAPI (blue) in Ad-cre treated MTEC derived from Kras and Kras/Cdc42 mice. Scale bar = 50 μm. (b) Crystal violet staining of MTEC derived from Kras and Kras/Cdc42 mice at 72 h with or without Ad-Cre treatment. (c) Immunofluorescent staining of ZO1 (Green) and DAPI (blue) in Ad-cre treated MEF derived from Kras and Kras/Cdc42 mice. Scale bar = 50 μm. (d) Growth of MEF derived from indicated mice determined by MTT assay during 6 continuous days of cell culture. (e) MTT assay indicated growth of MDCK cell line transfected with indicated vector at 72 h (low density) and 120 h (high density) relative to control (12 h). ***P < 0.001. (f) Quantitative PCR showing the knockdown efficiency of indicated vector in MCDK. (g) Immunofluorescent double staining of Phalloidin (Red) and DAPI (blue) in 3D cultured MDCK expressing KRAS-copGFP (top) or KRAS-shCdc42-copGFP (bottom). Scale bar = 20 μm.
Figure 4Lineage-specific deletion of Cdc42 in Club cells and AECII in Kras mouse model. (a) Immunohistochemical staining for SP-C and CCSP in lung tumors from Kras and Kras/Cdc42 mice. The dashed line indicated the bronchiole. Br: Bronchiole. Scale bar = 50 μm. (b) Representative photos of CCSP-CreERT2/Rosa26R -LacZ (upper panel) or SPC-CreERT2/Rosa26R-LacZ (lower panel) mice lung sections at 4 weeks post tamoxifen administration. β-galactosidase staining (blue) indicates targeted cell. The upper panel is co-stained with CCSP and the bottom is co-stained with SP-C. Scale bar = 50 μm. (c) A brief scheme of mouse crossing of SPC-CreERT2 and CCSP-CreERT2 allele with Kras or Kras/Cdc42 mice. (d) Representative pathology and immunohistochemical staining for SP-C and CCSP of lung tumors derived from SPC-Cre-ERT2/Kras (SK), SPC-Cre-ERT2/Kras/Cdc42 (SKC), CCSP-Cre-ERT2/Kras (CK) and CCSP-Cre-ERT2/Kras /Cdc42 (CKC) mice at 8 weeks post Ad-Cre treatment. Br: Bronchiole; Al: Alveoli. Scale bar = 500 μm for H&E, Scale bar = 50 μm for immunostaining. (e) Statistical analyses of the number of alveolar and bronchiolar tumors found in SK and SKC mice. Data were shown as mean ± s.e.m. *P < 0.05. (f,g) Statistical analyses of the number of alveolar and bronchiolar tumors (f) and the percentage of bronchiolar tumors (g) found in CK and CKC mice. Data were shown as mean ± s.e.m. ***P < 0.001.
Figure 5CDC42 expression positively correlates with alveolar marker SP-A expression in human lung adenocarcinoma. (a) Representative group (low, medium, high) of immunohistochemical staining for SP-C and CDC42 in 84 human lung adenocarcinoma samples. Scale bar = 50 μm. (b) Expression level of CDC42 or SP-A in 84 human lung adenocarcinoma samples. Scale bar = 50 μm. (c) Pearson correlation analysis showed a significant positive correlation between CDC42 expression and SP-A expression (P < 0.01, r = 0.3436) in 84 human lung adenocarcinoma. Full line represents linear regression of data.
Figure 6Schematic illustration of the function of CDC42 in lung cancer. In this study, we have identified an unexpected cell type-dependent role of CDC42 in lung tumorigenesis. In type II alveolar epithelial cells (AECII), Cdc42 loss strongly prevents Kras-driven neoplastic transformation, establishing the tumor-promotive role of CDC42. The pseudostratified or single-layer polarized Club cells, are separated by apical junctions which function as physical barrier by providing a tight seal between the membranes of the neighboring cells. These internal physical barriers of the neighboring cells function as a non-cell-autonomous tumor suppressor to restrict Kras-induced cell proliferation and prevent bronchiole tumor formation. Loss of core polarity protein CDC42 disrupted cell polarity and cell-cell contact inhibition, thereby leading to Kras induced bronchiole papillary hyperplasia. Green: normal cells; Pink: genetically mutated cells.